Alzamend Neuro, Inc. · NASDAQ:ALZN
Alzamend Neuro — Investor Presentation (May 2024)
30 slides from Alzamend Neuro's investor presentation, May 15, 2024
Slide 1: Corporate Presentation May 2024
Alzamend Neuro, Inc. Corporate Presentation May 2024
Slide 2: Safe Harbor Statement
SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of Alzamend Neuro, Inc . (the “Company” or “Alzamend”) contain “forward looking statements” within the meaning of Section 27 A of the Securities Act of 1933 , as amended, and Sect
Slide 3: Table of Contents
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. TABLE OF CONTENTS 3 4 - 8 Company Overview Introduction 9 Alzheimer’s Disease Overview of Indications 10 Bipolar Disorder 11 12 Major Depressive Disorder Post - Traumatic Stress Disorder 13 General Sc
Slide 4: Company Overview: Introduction
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION NASDAQ: ALZN 4 Biopharmaceutical Industry Small Molecule / Cell Therapy Sector 2016 Founded June 15, 2021 IPO $280k (Per our 10 - Q filed on March 25, 2024) Last Reported
Slide 5: Lead Drug Candidate – Ionic Cocrystal of Lithium (AL001)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION Lead Drug Candidate – Ionic Cocrystal of Lithium (AL001) 5 Market Opportunity Potential Replacement to Marketed Lithium Therapies Multiple Indications » 43.5 million U.S.
Slide 6: Reference to AL001: Current Marketed Lithium Carbonate
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION Reference to AL001: Current Marketed Lithium – Lithium Carbonate 6 Published Clinical Efficacy Studies For Alzheimer’s Challenges Usage For BD , MDD, PTSD » Forlenza , 20
Slide 7: Company Overview: Pipeline
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. 7 INTRODUCTION Company Overview FDA Approval Phase III Phase II Phase I Pre - Clinical Indication Product Candidate • Alzheimer’s Disease AL001 • Bipolar Disorder • Major Depressive Disorder • Post -
Slide 8: Company History and Current Pipeline
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Company Overview INTRODUCTION Company History Current Pipeline 8 AL001 (aka LISPRO): • a patented ionic cocrystal technology delivering a therapeutic combination of lithium , salicylate and proline fo
Slide 9: Overview of Alzheimer's Disease
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzheimer’s Disease OVERVIEW OF ALZHEIMER’S DISEASE 9 Alzheimer’s Disease : Alzheimer’s Disease is an irreversible, progressive brain disorder that slowly destroys memory and cognitive skills , and ev
Slide 10: Overview of Bipolar Disorder
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Bipolar Disorder OVERVIEW OF BIPOLAR DISORDER 10 Bipolar Disorder : Bipolar Disorder is a mental illness that causes unusual shifts in a person’s mood, energy, activity levels, and concentration . The
Slide 11: Overview of Major Depressive Disorder
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Major Depressive Disorder OVERVIEW OF MAJOR DEPRESSIVE DISORDER 11 Major Depressive Disorder : Major Depressive Disorder , commonly known as clinical depression , is one of the most common mental diso
Slide 12: Overview of Post-Traumatic Stress Disorder
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Post - Traumatic Stress Disorder OVERVIEW OF POST TRAMATIC STRESS DISORDER 12 Post - Traumatic Stress Disorder : PTSD is a mental and behavioral disorder that can develop because of exposure to a trau
Slide 13: General Scientific Overview
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Our Science GENERAL SCIENTIFIC OVERVIEW 13 Status Strength Synopsis Therapeutic Drug ▪ Reported Topline data of Phase IIA Multiple Ascending Dose Clinical Trial in June 2023. (www.clinical
Slide 14: AL001 Phase I Trial
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 Phase I Trial 14 Status Description Study Title Study No. Completed • To assess the relative bioavailability of the AL001 lithium formulation relative to a marketed lithium carbonate formulation
Slide 15: Select Results from Phase I Trial
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Safety/Tolerability: Primary Endpoint Met Select Results from Phase I Trial 15 » AL001 was shown to be safe and well - tolerated in healthy adult subjects » No serious adverse events and no deaths wer
Slide 16: AL001 Phase IIA Trial
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 Phase IIA Trial 16 Status Description Study Title Study No. • Reported Topline data of Phase IIA Multiple Ascending Dose Clinical Trial in June 2023 . (www.clinicaltrials.gov, identifier: NCT053
Slide 17: Topline Results from Phase IIA Trial
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Identify Maximum Tolerated Dose: Established Topline Results from Phase IIA Trial 17 » Identified dose of lithium at a lithium carbonate equivalent dose of 240 mg 3 - times a day (“TID”), is designed
Slide 18: ALZN002 Phase I/IIA Trial
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. ALZN002 Phase I/IIA Trial 18 Status Description Study Title Study No. Phase I/IIA Clinical Trial Initiated in March 2023 ( www.clinicaltrials.gov, identifier: NCT05834296 ), paused in February 2024 an
Slide 19: AL001 (aka LISPRO)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 (aka LISPRO ) 19 • AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium , salicylate, and proline. • AL001 exhibits improved non - clinical pharmacokine
Slide 20: AL001 (aka LISPRO) Preclinical Results
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 (aka LISPRO) 20 The results of our preclinical studies, conducted from May 2016 to June 2017 , are summarized below : • AL 001 had no effect on renal COX 2 activity ( Tg - Ctrl vs . AL 001 : p >
Slide 21: AL001 (aka LISPRO) Preclinical Studies
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. AL001 (aka LISPRO) 21 • Our pre - clinical studies encompassed the treatment of 28 transgenic (or genetically modified) and 10 non - transgenic mice with lithium carbonate and AL001. • Female APPSWE/P
Slide 22: Overview of ALZN002 (aka E22W)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of ALZN002 (aka E22W) 22 • Our goal is to develop an Alzheimer’s Aß vaccine candidate that will be devoid of the problems associated with current vaccine therapies. Our studies concluded the
Slide 23: Overview of ALZN002 (aka E22W)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of ALZN002 (aka E22W) 23 • We illustrated our result by using Aß peptide pulsed Dendritic Cells (“DC”) as a vaccine in Tg APP/PS1 mice. • Aß 1 - 42 with different mutation were synthesized an
Slide 24: Overview of Alzamend Neuro's Intellectual Property (Licensed Patents)
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Alzamend Neuro’s Intellectual Property (Licensed Patents) ALZAMEND NEURO 24 Patent # Expiration Date Date Issued Date Filed Therapeutic Drug Patent Type Title of Patent 9,603,869 05/21/203
Slide 25: Overview of Top Alzheimer's Disease Drugs on the Market
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Top Alzheimer’s Disease Drugs on the Market COMPETITIVE LANDSCAPE Aricept Exelon Namenda Leqembi A Aricept – Eisai Co., Ltd., Financial Results for Fiscal 2022(3/31/2023 for JPY FX) https:
Slide 26: Overview of Market Opportunity for AL001 and ALZN002
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Overview of Market Opportunity for AL001 and ALZN002 COMPETITIVE LANDSCAPE 26 Global (Including US) United States Patient Population 280 Million² 21 Million¹ MDD 284 Million² 9 Million¹ PTSD 55 Millio
Slide 27: Alzamend Leadership Team
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzamend Leadership Team ALZAMEND NEURO 27 Stephan Jackman Chief Executive Officer and Director 20+ years multi - industry experience, specialized in Biotech and Pharmaceutical Kenneth S. Cragun Senio
Slide 28: Alzamend Scientific Advisory Board
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Alzamend Scientific Advisory Board ALZAMEND NEURO 28 Thomas M. Wisniewski, M.D. Director, NYU Langone’s Pearl I. Barlow Center for Memory Evaluation and Treatment 300+ Peer - Reviewed Medical Journal
Slide 29: Alzamend Board of Directors
Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission. Lynne Fahey McGrath, Ph.D. Regulatory Affairs and Product Development Consultant 30+ years experience, Biotech and Pharmaceuticals M.P.H./Ph.D., Public Health from UMDNJ – Robert Wood Johnson Medical
Slide 30: Contact Us
CONTACT US 3480 Peachtree Road NE 2 nd Floor, Suite 103 Atlanta, GA 30326 +1 (844) 722 - 6333 Info@alzamend.com www.alzamend.com